ArticleTherapeutic innovation & regulatory science2021

Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

Tomoko Matsumoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.